Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial, page-70

This is a very important point D2. Also take into account that the CHM trial was as a fourth line of treatment, the others were 2nd. The CHM patient cohort had already had Three lines of treatment gaol them. They were in a very bad way.

The expansion trial now underway is as a second line of treatment, so hopefully we get even better results from this.

There is enough money in the bank to get all four trials through to early next year. Lots of potential pivot points between now and then. CHM will have two novel CarT drugs hitting arms, and two trials running with NK cells. Some of those trials are funded by others. Total EV is around the same price as a house (a nice house though). Its crazy, but what an opportunity. Still with risk of course.

All we have to do is wait.

One of my wife's work mates succumbed to GBM some years ago. 8 months from being diagnosed. This is a horrible disease. There is no SOC. I really hope CHM can offer sufferers some hope.